NCT04222686View on ClinicalTrials.gov

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

April 30, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Perindopril Arginine

10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

DRUG

Losartan Potassium

100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.

Trial Locations (1)

Unknown

Yaounde Central Hospital, NAtional Obesity Center, Yaoundé

All Listed Sponsors
lead

Yaounde Central Hospital

OTHER_GOV

NCT04222686 - Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients | Biotech Hunter | Biotech Hunter